Country: United States
Language: English
Source: NLM (National Library of Medicine)
DULOXETINE HYDROCHLORIDE (UNII: 9044SC542W) (DULOXETINE - UNII:O5TNM5N07U)
NCS HealthCare of KY, LLC dba Vangard Labs
DULOXETINE HYDROCHLORIDE
DULOXETINE 30 mg
ORAL
PRESCRIPTION DRUG
Duloxetine delayed-release capsules, USP are indicated for the treatment of: - Major Depressive Disorder[see Clinical Studies 14.1] - Generalized Anxiety Disorder[see Clinical Studies 14.2] - Diabetic Peripheral Neuropathy[see Clinical Studies 14.3] - Chronic Musculoskeletal Pain[see Clinical Studies 14.5] Monoamine Oxidase Inhibitors (MAOIs) — The use of MAOIs intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. The use of duloxetine delayed-release capsules within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [see Dosage and Administration (2.8) and Warnings and Precautions (5.4)]. Starting duloxetine delayed-release capsules in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin synd
Duloxetine delayed-release capsules, USP 20 mg are size '4' hard gelatin capsules having light blue cap and body, imprinted as '20 mg' on the body and '1109' on the cap with black ink, containing off white to reddish brown colored pellets. Duloxetine delayed-release capsules, USP 30 mg are size '3' hard gelatin capsules having blue cap and milky white body, imprinted as '30 mg' on the body with black ink and '1110' on the cap with white ink, containing off white to reddish brown colored pellets. Blistercards of 15 NDC 0615-8203-05 Blistercards of 30 NDC 0615-8203-39 Duloxetine delayed-release capsules, USP 60 mg are size '1' hard gelatin capsules having opaque blue cap and yellow body, imprinted as '60 mg' on the body and '1111' on the cap with white ink, containing off white to reddish brown colored pellets. Blistercards of 15 NDC 0615-8204-05 Blistercards of 30 NDC 0615-8204-39 Store at 20° to 25°C (68° to 77°); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
DULOXETINE HYDROCHLORIDE- DULOXETIN HYDROCHLORIDE CAPSULE, DELAYED RELEASE NCS HealthCare of KY, LLC dba Vangard Labs ---------- MEDICATION GUIDE Duloxetine (doo-LOX-e-teen) Delayed-Release Capsules, USP Read the Medication Guide before you start taking duloxetine delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk to your healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression, other serious mental illnesses, and suicidal thoughts or actions? 1. Duloxetine delayed-release capsules and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. 2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts or actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness). 3. How can I watch for and try to prevent suicidal thoughts and actions? • Pay close attention to any changes in mood, behavior, actions, thoughts, or feelings, especially sudden changes. This is very important when an antidepressant medicine is started or when the dose is changed. • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Call your healthcare provider right away if you have any of the following symptoms, or feelings, esp Read the complete document
DULOXETINE HYDROCHLORIDE- DULOXETIN HYDROCHLORIDE CAPSULE, DELAYED RELEASE NCS HEALTHCARE OF KY, LLC DBA VANGARD LABS ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DULOXETINE DELAYED- RELEASE CAPSULES, USP SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DULOXETINE DELAYED-RELEASE CAPSULES, USP. DULOXETINE DELAYED-RELEASE CAPSULES USP, FOR ORAL USE. INITIAL U.S. APPROVAL: 2004 WARNING: SUICIDAL THOUGHTS AND BEHAVIORS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS TAKING ANTIDEPRESSANTS (5.1) MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS (5.1) RECENT MAJOR CHANGES Warning and precautions: Serotonin Syndrome (5.4) 01/2017 INDICATIONS AND USAGE Duloxetine delayed-release capsules, USP are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: (1) Major Depressive Disorder (MDD) (1) Generalized Anxiety Disorder (GAD) (1) Diabetic Peripheral Neuropathic Pain (DPNP) (1) Chronic Musculoskeletal Pain (1) DOSAGE AND ADMINISTRATION Take duloxetine delayed-release capsule once daily, with or without food. Swallow duloxetine delayed- release capsule whole; do not crush or chew, do not open capsule. Take a missed dose as soon as it is remembered. Do not take two doses of duloxetine delayed-release capsules at the same time. (2) Indication Starting Dose Target Dose Maximum Dose MDD (2.1) 40 mg/day to 60 mg/day AcuteTreatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 120 mg/day GAD (2.2) Adults 60 mg/day 60 mg/day (once daily) 120 mg/day DPNP (2.3) 60 mg/day 60 mg/day (once daily) 60 mg/day Chronic Musculoskeletal Pain (2.5) 30 mg/day 60 mg/day (once daily) 60 mg/day Some patients may benefit from starting at 30 mg once daily (2) There is no evidence that doses greater than 60 mg/day confers additional benefit, while some adverse Read the complete document